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Objective: To estimate the extent to which varus malalignment, a source of abnormal intra-articular
stresses in the medial tibiofemoral compartment and risk factor for progression of knee osteoarthritis
(OA), may have diminished the structure-modifying beneﬁt of doxycycline in knee OA.
Methods: Post hoc treatment group comparisons from a randomized, placebo-controlled trial of the effect
of doxycycline (100 mg, twice daily) on medial joint space narrowing (JSN) in subgroups of varus and
non-varus OA knees. Subjects (N¼ 379 with X-ray follow-up) were obese 45e64-year-old women with
unilateral knee OA at baseline. JSN was measured manually in semiﬂexed anteroposterior (AP) radio-
graphs acquired with standardized ﬂuoroscopic positioning. The anatomic-axis angle (AAA) was
measured in each baseline radiograph and transformed to an estimate of the mechanical-axis angle
(MAAest) using a validated regression equation. Knees with MAAest< 178 were classiﬁed as varus.
Results: In our original comparison with placebo, doxycycline slowed the rate of medial JSN in OA knees
by 38% at 16 months and by 33% at 30 months. Among non-varus OA knees, 16-month JSN in the
doxycycline group was 44% slower than in the placebo group (0.09 vs 0.16 mm/year, P¼ 0.080), and 39%
slower at month 30 (0.10 vs 0.17 mm/year, P¼ 0.026). JSN in varus knees (0.20e0.27 mm/year) was more
rapid than in non-varus knees (P¼ 0.083) and unaffected by doxycycline.
Conclusion: Varus malalignment negated the slowing of structural progression of medial-compartment
OA by doxycycline. To our knowledge, this is the ﬁrst report documenting that static varus angulation can
negate a pharmacologic structure-modifying effect.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
While recent reviews have highlightedmethodological advances
that have increased the feasibility of clinical trials of disease-
modifying OA drugs (DMOADs)1e3, the results of randomized
controlled trials (RCTs) of drugs intended to slow the structural
damage of OA have been inconsistent. One reason for this incon-
sistency may be that pharmacotherapy intended to slow the dete-
rioration of articular cartilage does nothing to negate the effects of
abnormal intra-articular stresses that are the prime force in the
etiopathogenesis and progression of common garden-variety OA4.
We have shown that, compared to placebo, treatment with
doxycycline slowed the rate of radiographic joint space narrowing
(JSN) in the medial-compartment of knees with established OA5.: Steven A. Mazzuca, Indiana
cine, Rheumatology Division,
dianapolis, IN 46202, USA.
a).
s Research Society International. PBecause varus malalignment increases loading of the medial
tibiofemoral compartment6 and, hence, the risk of OA progression7,
it may have attenuated the pharmacologic beneﬁt of doxycycline.
Herein we describe results of subgroup analyses from this trial to
ascertain whether varus malalignment decreased the structure-
modifying effect of doxycycline in knee OA.
Methods
All procedures for this RCT, including written informed consent,
were approved by the Institutional Review Board (IRB) of Indiana
University Purdue University Indianapolis, where the coordinating
Center was located and by IRBs at other participating institutions5.
Subjects
The original sample of the doxycycline RCT consisted of 431
women recruited at six clinical centers in the United States. All
were 45e64 years of age, in the upper tertile of sex-, age- and race-
based norms for body mass index (BMI) and had unilateral knee OAublished by Elsevier Ltd. All rights reserved.
Table I
Non-annualized medial-compartment JSN (mean SD, mm) by treatment group:
results in varus and non-varus OA knees
Varus OA knees
(MAAest< 178)
Non-varus OA knees
(MAAest 178)
Doxycycline Placebo P* Doxycycline Placebo P*
16-Month JSN 0.26 0.39 0.36 0.57 0.230 0.12 0.42 0.21 0.52 0.080
N of knees 37 45 151 146
30-Month JSN 0.49 0.64 0.55 0.62 0.448 0.26 0.58 0.42 0.73 0.026
N of knees 35 42 146 138
Note: estimated MAAest was based on measurement of the AAA12.
* From mixed-effect (repeated measures) linear models adjusted for treatment
group, baseline knee pain and JSW, visit (interim or closeout), clinical center,
treatment groupeclinical center interaction and treatment groupevisit interaction.
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Data for the present analysis were derived from 379 subjects (88%
of those randomized) who underwent the interim (16-month)
radiographic examination and 361 subjects (84% of those
randomized) who completed the closeout (30-month) assessment.
Measurement of JSN
The primary outcome of the RCT was radiographic JSN in the
medial tibiofemoral compartment. As previously reported5, semi-
ﬂexed anteroposterior (AP) knee radiographs were acquired at
baseline and at months 16 and 30 according to BucklandeWright’s
protocol for ﬂuoroscopically standardized radioanatomic posi-
tioning of the knee9. Quantitative JSN estimates were based on
serial magniﬁcation-corrected measurements of minimum joint
space width (JSW) obtained with a screw-adjustable calipers and
graduated loupe according to the method described by Lequesne10.
Measurement of malalignment
The anatomic-axis angle (AAA) in the frontal plane was
measured by one of two readers (RC, SAM) in each baseline
radiograph of the index (OA) knee, following the methods
described by Kraus et al.11. AAAwas measured by goniometer along
the medial aspect of the lower extremity. The AAA was formed by
lines that began at points bisecting the widths of the proximal
femur and distal tibia (w10 cm from the joint space) and converged
at a point midway between the tibial spines. Inter-reader repro-
ducibility (intra-class correlation) of AAA measurements from 36
randomly selected radiographs was 0.95.
Measurements of AAA were transformed into estimates of the
mechanical-axis angle (MAAest) by use of the regression equation
(MAAest¼ 0.915AAAþ 13.895, R2¼ 0.77) validated by Hinman et
al.12. In their study, MAA estimated from AAA measured in knee
radiographs accounted for 77% of variation in actual MAAmeasured
in concurrent long-limb radiographs. Knees in the present study
with MAAest< 178 were classiﬁed as exhibiting varus angulation,
by norms established by Moreland et al.13.
Analysis
Separate treatment group comparisons were performed on
subgroups of varus and non-varus OA knees using the same mixed-
effect (repeated measures) linear model employed in the original
analysis of doxycycline effects5. To test whether the rates of medial-
compartment JSN in varus and non-varus subgroups were similar,
we employed an additional repeatedmeasures model that included
all knees and a dichotomous indicator of varus angulation
(MAAest< 178 vs 178) as a covariate. Terms were included in
each model to account for interactions between treatment group
and visit, clinical center and varus malalignment (third model
only). All comparisons were adjusted for baseline knee pain and
JSW, visit (interim or closeout) and clinical center.
Results
Of the 379 subjects who underwent the interim (month 16)
radiographic examination, the index (OA) knee exhibited varus angu-
lationatbaseline in82 (22%).At closeout, 77of the361 indexknees that
were available for analysis (21%) had exhibited varus angulation in the
baseline radiograph. As described previously5, all subjects enrolled in
the RCT were obese, middle-aged women with unilateral K&L grades
2e3 OA at baseline. Subgroups of subjects with varus and non-varus
index knees were similar with respect to age, BMI, race and baseline
knee pain. However, varus knees were signiﬁcantly more likely thannon-varus knees to have K&L grade 3 OA at baseline (64% vs 32%,
P< 0.0001). Consistentwithdeﬁnitions of OA severity byK&L criteria8,
mean JSWinvaruskneeswas signiﬁcantly smaller at baseline than that
in non-varus knees (2.77 vs 3.90 mm, P< 0.0001).
Table I contains a summary of non-annualized JSN in the
doxycycline and placebo treatment arms among subgroups of varus
and non-varus OA knees. In both treatment groups, over both
intervals, varus knees exhibited a greater loss of JSW than non-
varus knees (P¼ 0.083 after adjustment for treatment group,
baseline knee pain and JSW, visit, clinical center, and interactions
between treatment group and both visit and clinical center).
Notably, group comparisons among varus knees showed similar
rates of JSN in the two treatment groups, as reﬂected in average loss
of minimum medial JSW at both month 16 (0.26 vs 0.36 mm,
P¼ 0.230) and month 30 (0.49 vs 0.55 mm, P¼ 0.448). In contrast,
among non-varus knees, the difference between treatment groups
with respect to mean JSN favored doxycycline at both intervals. The
mean difference between treatment groups was marginally
signiﬁcant as early as month 16 (0.12 vs 0.21 mm, P¼ 0.080) and
unequivocally signiﬁcant at month 30 (0.26 vs 0.42 mm, P¼ 0.026).
Discussion
Knee malalignment was not an exclusion criterion for the
doxycycline trial, which we initiated in 1996, or for many other
contemporaneous DMOAD trials in knee OA. Of eight knee RCTs of
DMOADs that we reviewed previously3, only one14 excluded
subjects with “clinically important” axial deviation of the lower
extremity. Although current protocols for RCTs of putative DMOADs
now often exclude subjects with signiﬁcant varus or valgus defor-
mity on the presumption that the efﬁcacy of the drug may be
diminished in such patients, to our knowledge, this is the ﬁrst
report documenting that static varus angulation can negate
a pharmacologic structure-modifying effect.
In our original comparison of outcomes in active treatment and
placebo groups5, oral doxycycline, 100 mg bid, slowed the annual-
ized rate of medial JSN in OA knees by 38% at 16 months (P¼ 0.027)
and by 33% at 30months (P¼ 0.017). The post hoc subgroup analyses
in the present study indicate, however, that doxycycline had no
signiﬁcant effect on the comparatively rapid rate of JSN in themedial
tibiofemoral compartment of the varus knee (0.20e0.27 mm/year).
These results are in marked contrast to the outcomes in non-varus
knees, inwhich doxycycline slowed JSN by 43% at month 16, and by
38% at month 30, relative to placebo (Table I).
Our decision to combine for analysis kneeswith neutral or valgus
angulation at baseline into a “non-varus” subgroup was intended to
maximize the power of treatment group comparisons to elucidate
howvarusmalalignment inﬂuenced the effect of doxycycline on the
primary outcome, JSN in the medial tibiofemoral compartment.
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and a corresponding pseudo-widening of medial joint space, the
valgus knee may have been ill-suited for the demonstration of
a DMOAD effect on progression of JSN in the medial-compartment.
To explore the extent to which inclusion of subjects with valgus
knees in the doxycycline RCT made it more difﬁcult to demonstrate
a signiﬁcant DMOAD effect, we examined the annualized rate of
medial-compartment JSN over 30 months (mean SE) in OA knees
with varus, neutral or valgus angulation at baseline (Fig. 1).
Consistentwith the results shown inTable I, at 30months the rate of
JSN in the 35 varus knees of subjects treated with doxycycline was
only 11% slower than that in 42 varus knees of subjectswho received
placebo. In contrast, in neutrally aligned knees (N¼ 37 and 49,
respectively), doxycycline slowed the annual rate of medial JSN by
nearly 50%, compared to placebo. Two ﬁndings are apparent in data
from knees with valgus angulation (MAAest 181) at baseline: the
ﬁrst is that, not surprisingly, the rate ofmedial JSNwasmuch slower
in valgus knees than in either varus or neutral knees. Second,
despite less rapid JSN in the medial-compartment, the mean rate of
JSN in the 109 valgus knees of subjects treatedwith doxycyclinewas
25% slower than that in the 89 valgus knees of those receiving
placebo.
These data suggest that while the rapid medial-compartment
JSN in varus knees was unaltered by treatment with doxycycline,
the drug retarded JSN in valgus knees e although to an extent only
about half as great as in neutrally aligned knees. Inclusion of valgus
knees in the RCT did not preclude detection of a signiﬁcant
protective effect of doxycycline against medial JSN in either our
original analysis of all OA knees5 or in the current analysis of the
non-varus subgroup.
This post hoc analysis has some limitations: ﬁrst, restriction of
enrollment in the doxycycline RCT to obese women may have
limited the generalizability of any conclusions about the beneﬁts of
doxycycline as a DMOAD in the OA population at large. However,
this narrow focus of the RCT did not compromise its value as
a demonstration of the concept of structure-modiﬁcation in knee
OA e or of the present subgroup analysis as an exploration of the
possible moderating effects of malalignment.
Second, the percentage of knees that were classiﬁed as having
varus angulation at baseline (21e22%) was smaller than expected
and may have limited our power to detect treatment effects in thisFig. 1. Mean rate (SE) of medial-compartment JSN over 30 months in varus, neutral
and valgus knees: comparisons of knees treated with doxycycline and placebo. For
varus, neutral and valgus knees, Ns in the doxycycline treatment group were 35, 37 and
109, respectively. For the placebo arm of the RCT, the corresponding Ns were 42, 49 and
89, respectively.subgroup. This low percentage is likely due, in part, to our exclusion
of subjectswith K&L grade 4 knee OA at baseline. In addition, a skew
in the distribution of MAAest, away from the varus and toward the
valgus end of the spectrum, may be a limitation inherent in the
measurement of AAA with short (10e12 cm) segments of the tibial
and femoral shafts15 or a bias in the arithmetic transformation of
AAA measurements into estimates of MAA12. However, the small
(9%) difference in 30-month JSN between varus knees assigned to
thedoxycyclineorplacebogroups (Fig.1) suggests that the statistical
power of treatment group comparisons among knees classiﬁed as
varus in this analysis was not a signiﬁcant limitation.
Third, malalignment itself is only a crude indicator of an adverse
biomechanical environment, in which abnormal intra-articular
stress drives the etiopathogenetic mechanisms that underlie joint
breakdown in OA and may counteract attempts at physiologic or
pharmacologic repair4. The evidence argues that it is not varus per
se, or obesity, per se, that is detrimental to the knee, but the
consequences of the resulting alteration in mechanical loading for
the articular cartilage and subchondral bone. However, a recent
report suggesting that leptin, which is produced by adipose tissue,
protected against development of knee OA in markedly obese
mice16, suggests the story may be more complicated.
Varusevalgus malalignment, as measured in a full-limb radio-
graph or estimated in a knee ﬁlm, is an indication of static mala-
lignment, whereas a varus thrust visualized during gait reﬂects
dynamic malalignment. Varusevalgus alignment is a key determi-
nant of the peak adductor moment, a measure of the magnitude of
the intrinsic compressive load on the medial tibiofemoral
compartment in stance. Varus further increases the medial-
compartment load during gait; valgus increases stress in the
lateral compartment17. Miyazaki et al.18 found that the peak
adductor moment predicted X-ray progression in subjects with
medial-compartment OA.
Chang et al.19 reported that a visualized varus thrust was asso-
ciated with a four-fold increase in the likelihood of progression of
medial tibiofemoral compartment OA. Among varus knees, the
presence of a visualized thrust further increased the odds of
progression of medial-compartment JSN three-fold. Thus, among
OA knees with static varus malalignment, a subset that is charac-
terized by the presence of a thrust appears to be at particularly high
risk for OA progression. However, a thrust effect on progression (i.e.,
JSN) was apparent in knees with relatively mild varus alignment
(<5) but not in those with more severe varus. Although approxi-
mately 70% of the total force across the normal knee has been
shown to act on the medial-compartment during level walking20,
Chang et al.19 considered that with increasing varus malalignment,
nearly 100% of the load is transmitted medially and hence, in the
presence of higher degrees of varus, thrust has little additional
impact. In any event, the possibility should be considered that
dynamic, as well as static, loading of the knee might mitigate the
structure-modifying effect of a DMOAD.
The signiﬁcance of the present ﬁndings for the design of clinical
trials of DMOADs should be viewed in light of published evidence21
that argues powerfully that the underlying problem in common,
garden-variety OA is a quantitative or qualitative abnormality in
intra-articular stress, due to a variety of causes; and that if the
abnormal stress is eliminated, the OA joint can heal, with marked
structural and symptomatic improvement. We have suggested that
if the abnormal stress on the OA joint is not corrected, the likeli-
hood is small that a putative DMOAD will be efﬁcacious21.Our
present data support that earlier suggestion. We recommend that
future clinical trials of pharmacologic or non-pharmacologic ther-
apies aimed at disease modiﬁcation control the extraneous effects
of biomechanical factors (either through exclusion criteria or
through measurement and stratiﬁed allocation to treatment
S.A. Mazzuca et al. / Osteoarthritis and Cartilage 18 (2010) 1008e1011 1011groups). Furthermore, we suggest that DMOAD effects may be
attenuated also by genetic or developmental abnormalities in joint
shape22,23 and by neuromuscular abnormalities (e.g., sarcopenia,
proprioceptive defects) that impair micro-coordination and, like
malalignment, can increase intra-articular stress.
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